The 16th International Workshop on Non-Hodgkin Lymphoma (iwNHL) took place in Nice, France, from September 21–23, 2018.

This year's meeting highlighted efforts to understand the biology of different NHL subtypes, as well as novel therapeutic strategies to optimize clinical care.

As the iwNHL's official media partner, VJHemOnc was there to cover this exciting new content.

iwNHL 2018

21–23 September 2018 | Nice, France

iwNHL 2018

21–23 September 2018 | Nice, France

The 16th International Workshop on Non-Hodgkin Lymphoma (iwNHL) took place in Nice, France, from September 21–23, 2018.

This year's meeting highlighted efforts to understand the biology of different NHL subtypes, as well as novel therapeutic strategies to optimize clinical care.

As the iwNHL's official media partner, VJHemOnc was there to cover this exciting new content.

The challenging field of hem-onc therapeutics 2:03
The challenging field of hem-onc therapeutics
Steven Rosen • 21 Sep 2018
Non-hodgkin lymphoma advances in 2018 1:09
Non-hodgkin lymphoma advances in 2018
Steven Rosen • 21 Sep 2018
CAR-T super users: teams to closely monitor patients receiving CAR T-cells 2:09
CAR-T super users: teams to closely monitor patients receiving CAR T-cells
Bianca Santomasso • 21 Sep 2018
Nuances of systemic lymphoma and CNS lymphoma 1:01
Nuances of systemic lymphoma and CNS lymphoma
Bianca Santomasso • 21 Sep 2018
CAR T-cell therapy: on the way to success 1:33
CAR T-cell therapy: on the way to success
Steven Rosen • 21 Sep 2018
Management of cytokine release syndrome and neurotoxicity: an emerging need 2:15
Management of cytokine release syndrome and neurotoxicity: an emerging need
Bianca Santomasso • 21 Sep 2018
Viral lymphomas: risk factors and treatments 8:24
Viral lymphomas: risk factors and treatments
Catherine Bollard et al. • 21 Sep 2018
Pathobiology and clinical management of T-cell lymphoma 6:32
Pathobiology and clinical management of T-cell lymphoma
Francine Foss et al.
Cellular therapy and drug access for viral lymphomas 9:57
Cellular therapy and drug access for viral lymphomas
Catherine Bollard et al. • 21 Sep 2018
Precision medicine in lymphoma 9:02
Precision medicine in lymphoma
Anas Younes et al. • 21 Sep 2018
Novel diagnostics & biomarkers for DLBCL and CTCL 8:01
Novel diagnostics & biomarkers for DLBCL and CTCL
Bjoern Chapuy et al. • 21 Sep 2018
Immunotherapy for NHL: checkpoint inhibitors, considerations & the future 7:43
Immunotherapy for NHL: checkpoint inhibitors, considerations & the future
John Gribben et al. • 21 Sep 2018
iwNHL day 2 highlights: bridging the gap to CAR T-cell therapy & precision medicine 11:58
iwNHL day 2 highlights: bridging the gap to CAR T-cell therapy & precision medicine
Anas Younes et al. • 22 Sep 2018
iwNHL 2018 day 1 highlights: T-cells, biomarkers & personalized medicine 12:32
iwNHL 2018 day 1 highlights: T-cells, biomarkers & personalized medicine
Catherine Bollard et al. • 21 Sep 2018
Novel targets and agents for lymphoma 7:45
Novel targets and agents for lymphoma
John Kuruvilla et al.
CAR T-cells in lymphoma: where are we now? 11:13
CAR T-cells in lymphoma: where are we now?
David Maloney et al. • 21 Sep 2018
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJHemOnc is intended for healthcare professionals